Login to Your Account



Corgentech Plummets As E2F Decoy Misses Again In Phase III

By Aaron Lorenzo


Thursday, March 31, 2005
It's the kind of mirror image Corgentech Inc. didn't want: Only a few months after reporting a Phase III failure for edifoligide (E2F Decoy), its partnered product with Bristol-Myers Squibb Co., the investigational drug again fell short in another Phase III study. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription